Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients

Summary

Patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative non-small-cell lung cancer (NSCLC) participated in this study following the failure of initial treatments. The ALK phosphorylation expression was detected in histologic samples of patients. patients with positive ALK phosphorylation expression were treated with crizotinib .

Timeline

Start

2018-01-01

Primary completion

2022-05-01

Completion

2023-03-01

Drugs

Indications